The main goal of this study is to evaluate the normal expression levels of microRNAs in NAF and blood to determine baselines that will lead to cut-off values for the detection of breast cancer. The results will be compared with microRNA levels…
Bron
Aandoening
Breast cancer
Ondersteuning
Onderzoeksproduct en/of interventie
Geen registraties gevonden.
Uitkomstmaten
Primaire uitkomstmaten
The main study parameters is the degree and patterns of microRNA expression in NAF and blood of healthy women, and to compare this with the pattern of women with breast cancer (ORNAMENT study, Trial NL6031)
Achtergrond van het onderzoek
Rationale: Breast cancer develops by the stepwise accumulation of interacting epigenetic and genetic events over time. While genetic events are specific processes that differ greatly between patients, epigenetic events are more generally occurring during breast cancer development. Therefore, epigenetic monitoring (in addition to genetic monitoring) could become a breakthrough in breast cancer prevention. Diagnostically there is a need for better procedures that can predict accurately who will and who will not develop breast cancer. Circulating miRNAs can be easily measured in body fluids such as nipple aspirate fluid (NAF) and blood, which could offer a promising minimally invasive method to complement current breast cancer screening methods. This study is part of a larger project that aims to assess the microRNA expression levels in NAF and blood of women with recently diagnosed breast cancer. Those expression levels will be compared to those obtained in this healthy control study. The results from this project will be further validated in a nested case-control study (NAF study). The ultimate goal is to develop a tool that enables a more accurate early prediction of the onset of breast cancer, to monitor development of microRNA expression patterns in NAF and blood of women at high risk for breast cancer.
Objective: The main goal of this study is to evaluate the normal expression levels of microRNAs in NAF and blood to determine baselines that will lead to cut-off values for the detection of breast cancer. The results will be compared with microRNA levels obtained just before primary surgery from patients with suspicion of, or histologically proven, breast cancer. We will perform stability analysis of candidate endogenous controls, and choose a microRNA that then can be used as endogenous control for real-time quantitation of miRNAs in NAF and blood in healthy subjects, women at high risk of developing breast cancer and breast cancer patients.
Study design: This study has a cross-sectional design and healthy women will be included. NAF and blood will be obtained once and the women will not be followed over time.
Doel van het onderzoek
The main goal of this study is to evaluate the normal expression levels of microRNAs in NAF and blood to determine baselines that will lead to cut-off values for the detection of breast cancer. The results will be compared with microRNA levels obtained just before primary surgery from patients with suspicion of, or histologically proven, breast cancer. We will perform stability analysis of candidate endogenous controls, and choose a microRNA that then can be used as endogenous control for real-time quantitation of miRNAs in NAF and blood in healthy subjects, women at high risk of developing breast cancer and breast cancer patients.
Onderzoeksopzet
Not applicable
Onderzoeksproduct en/of interventie
A onetime dose of 4 IE oxytocin nasal spray is administered prior to the nipple fluid aspiration (NFA) procedure. NAF is obtained through the use of a manual vacuum-system. In addition, three vials of blood will be taken
Publiek
Susana Patuleia
+31887557409 (Office manager of the Principal Investigator)
s.i.schoutenpatuleia-7@umcutrecht.nl
Wetenschappelijk
Susana Patuleia
+31887557409 (Office manager of the Principal Investigator)
s.i.schoutenpatuleia-7@umcutrecht.nl
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
- Female
- Healthy
- Non-lactating
- Over the age of 45 years
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
- Male
- Age under 45 years
- Bilateral ablative breast surgery
- Bilateral breast reduction with nipple graft
- Pregnancy or lactation
- Active breast infection
- Personal history of DCIS or invasive breast cancer
- > 20% risk of developing breast cancer
Opzet
Deelname
Voornemen beschikbaar stellen Individuele Patiënten Data (IPD)
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Geen registraties gevonden.
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
Register | ID |
---|---|
NTR-new | NL8987 |
Ander register | METC UMCU : METC 12-495 |